NAFLD: A multisystem disease

Journal of Hepatology

Volumn 62, Issue S1, 2015, Pages S47-S64

  Byrne, Christopher D ^a,b   Targher, Giovanni ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c University and Azienda Ospedaliera Universitaria Integrata of Verona   (Italy)

Author keywords

Cardiac arrhythmias; Cardiac disease; Cardiovascular disease; Chronic kidney disease; Hepatocellular carcinoma; Insulin resistance; Non alcoholic fatty liver disease; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

AORTA VALVE DISEASE; AORTIC VALVE SCLEROSIS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; EPIDEMIOLOGICAL DATA; FATTY LIVER; HEART ARRHYTHMIA; HEART DISEASE; HEART FUNCTION; HEART MUSCLE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LABORATORY TEST; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; MEDLINE; META ANALYSIS; METABOLIC SYNDROME X; MORTALITY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SCLEROSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; NON-ALCOHOLIC FATTY LIVER DISEASE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84930656108     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.12.012     Document Type: Review

References (147)

1. M.J. Armstrong, L.A. Adams, A. Canbay, and W.K. Syn Extrahepatic complications of nonalcoholic fatty liver disease Hepatology 59 2014 1174 1197
2. H.C. Masuoka, and N. Chalasani Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals Ann N Y Acad Sci 1281 2013 106 122
3. A. Tsuneto, A. Hida, N. Sera, M. Imaizumi, S. Ichimaru, E. Nakashima, and et al. Fatty liver incidence and predictive variables Hypertens Res 33 2010 638 643
4. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, and J.C. Cohen Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
5. M. Blachier, H. Leleu, M. Peck-Radosavljevic, D.C. Valla, and F. Roudot-Thoraval The burden of liver disease in Europe: a review of available epidemiological data J Hepatol 58 2013 593 608
6. G. Musso, R. Gambino, M. Cassader, and G. Pagano Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 43 2011 617 649
7. G. Musso, R. Gambino, J.H. Tabibian, M. Ekstedt, S. Kechagias, M. Hamaguchi, and et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis PLoS Med 11 2014 e1001680
8. G. Musso, M. Cassader, C. Olivetti, F. Rosina, G. Carbone, and R. Gambino Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis Obes Rev 14 2013 417 431
9. S.S. Lee, and S.H. Park Radiologic evaluation of nonalcoholic fatty liver disease World J Gastroenterol 20 2014 7392 7402
10. H.B. Holt, S.H. Wild, P.J. Wood, J. Zhang, A.A. Darekar, K. Dewbury, and et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects Diabetologia 49 2006 141 148
11. Y. Sumida, A. Nakajima, and Y. Itoh Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis World J Gastroenterol 20 2014 475 485
12. R. Hernaez, M. Lazo, S. Bonekamp, I. Kamel, F.L. Brancati, E. Guallar, and et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis Hepatology 54 2011 1082 1090
13. S.B. Reeder, I. Cruite, G. Hamilton, and C.B. Sirlin Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy J Magn Reson Imaging 34 2011 729 749
14. L.S. Szczepaniak, P. Nurenberg, D. Leonard, J.D. Browning, J.S. Reingold, S. Grundy, and et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab 288 2005 E462 E468
15. D.E. Kleiner, E.M. Brunt, N.M. Van, C. Behling, M.J. Contos, O.W. Cummings, and et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
16. S. Whalley, P. Puvanachandra, A. Desai, and H. Kennedy Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs Clin Med 7 2007 119 124
17. S. Romeo, J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L.A. Pennacchio, and et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat Genet 40 2008 1461 1465
18. Q.M. Anstee, G. Targher, and C.P. Day Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis Nat Rev Gastroenterol Hepatol 10 2013 330 344
19. J. Hyysalo, V.T. Mannisto, Y. Zhou, J. Arola, V. Karja, M. Leivonen, and et al. A population-based study on the prevalence of NASH using scores validated against liver histology J Hepatol 60 2013 839 846
20. J. Hyysalo, P. Gopalacharyulu, H. Bian, T. Hyotylainen, M. Leivonen, N. Jaser, and et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity Diabetes 63 2014 312 322
21. D.G. Mashek, and A.S. Greenberg Serum TAG analysis differentiates between genetic and obesity-associated NAFLD Diabetes 63 2014 42 44
22. J.H. Yoon, J.M. Lee, I. Joo, E.S. Lee, J.Y. Sohn, S.K. Jang, and et al. Hepatic fibrosis: prospective comparison of MR elastography and US shear wave elastography for evaluation Radiology 7 2014 132000
23. M. Ekstedt, L.E. Franzen, U.L. Mathiesen, L. Thorelius, M. Holmqvist, G. Bodemar, and et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 2006 865 873
24. M. Ekstedt, H. Hagstrom, P. Nasr, M. Fredrikson, P. Stal, S. Kechagias, and et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology 2014 10.1002/hep.27368 [Epub ahead of print]
25. M.R. Charlton, J.M. Burns, R.A. Pedersen, K.D. Watt, J.K. Heimbach, and R.A. Dierkhising Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 141 2011 1249 1253
26. R. de Marco, F. Locatelli, G. Zoppini, G. Verlato, E. Bonora, and M. Muggeo Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study Diabetes Care 22 1999 756 761
27. E.M. Brunt Nonalcoholic steatohepatitis Semin Liver Dis 24 2004 3 20
28. N.G. Ladep, S.A. Khan, M.M. Crossey, A.V. Thillainayagam, S.D. Taylor-Robinson, and M.B. Toledano Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations World J Gastroenterol 20 2014 1544 1553
29. J. Konfortion, V.H. Coupland, H.M. Kocher, W. Allum, M.J. Grocock, and R.H. Jack Time and deprivation trends in incidence of primary liver cancer subtypes in England J Eval Clin Pract 20 2014 498 504
30. J. Ertle, A. Dechene, J.P. Sowa, V. Penndorf, K. Herzer, G. Kaiser, and et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis Int J Cancer 128 2011 2436 2443
31. F. Stickel, and C. Hellerbrand Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications Gut 59 2010 1303 1307
32. B.Q. Starley, C.J. Calcagno, and S.A. Harrison Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection Hepatology 51 2010 1820 1832
33. G.A. Michelotti, M.V. Machado, and A.M. Diehl NAFLD, NASH and liver cancer Nat Rev Gastroenterol Hepatol 10 2013 656 665
34. B.C. Lee, and J. Lee Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance Biochim Biophys Acta 1842 2014 446 462
35. B.A. Beutler TLRs and innate immunity Blood 113 2009 1399 1407
36. S. Yoshimoto, T.M. Loo, K. Atarashi, H. Kanda, S. Sato, S. Oyadomari, and et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome Nature 499 2013 97 101
37. P.T. Campbell, C.C. Newton, A.V. Patel, E.J. Jacobs, and S.M. Gapstur Diabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults Diabetes Care 35 2012 1835 1844
38. G. Zoppini, U. Fedeli, N. Gennaro, M. Saugo, G. Targher, and E. Bonora Mortality from chronic liver diseases in diabetes Am J Gastroenterol 109 2014 1020 1025
39. M. Maximos, F. Bril, S.P. Portillo, R. Lomonaco, B. Orsak, D. Biernacki, and et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease Hepatology 61 2014 153 160
40. B. Balkau, C. Lange, S. Vol, F. Fumeron, and F. Bonnet Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. Study BMC Gastroenterol 10 2010 56
41. D.H. Lee, R. Blomhoff, and D.R. Jacobs Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 38 2004 535 539
42. T. Yamada, M. Fukatsu, S. Suzuki, T. Wada, T. Yoshida, and T. Joh Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup J Gastroenterol Hepatol 25 2010 352 356
43. K.C. Sung, W.S. Jeong, S.H. Wild, and C.D. Byrne Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes Diabetes Care 35 2012 717 722
44. M. Shibata, Y. Kihara, M. Taguchi, M. Tashiro, and M. Otsuki Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men Diabetes Care 30 2007 2940 2944
45. M. Okamoto, Y. Takeda, Y. Yoda, K. Kobayashi, M.A. Fujino, and Z. Yamagata The association of fatty liver and diabetes risk J Epidemiol 13 2003 15 21
46. C.H. Kim, J.Y. Park, K.U. Lee, J.H. Kim, and H.K. Kim Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults Diabet Med 25 2008 476 481
47. J.G. Fan, F. Li, X.B. Cai, Y.D. Peng, Q.H. Ao, and Y. Gao Effects of nonalcoholic fatty liver disease on the development of metabolic disorders J Gastroenterol Hepatol 22 2007 1086 1091
48. J.C. Bae, E.J. Rhee, W.Y. Lee, S.E. Park, C.Y. Park, K.W. Oh, and et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study Diabetes Care 34 2011 727 729
49. S.K. Park, M.H. Seo, H.C. Shin, and J.H. Ryoo The clinical availability of non-alcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5-years' prospective cohort study Hepatology 57 2012 1378 1383
50. A. Kasturiratne, S. Weerasinghe, A.S. Dassanayake, S. Rajindrajith, A.P. de Silva, N. Kato, and et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus J Gastroenterol Hepatol 28 2013 142 147
51. Y. Chang, H.S. Jung, K.E. Yun, J. Cho, Y.K. Cho, and S. Ryu Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population Am J Gastroenterol 108 2013 1861 1868
52. K.C. Sung, S.H. Wild, and C.D. Byrne Resolution of fatty liver and risk of incident diabetes J Clin Endocrinol Metab 98 2013 3637 3643
53. J.R. Morling, J.A. Fallowfield, I.N. Guha, L.D. Nee, S. Glancy, R.M. Williamson, and et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study J Hepatol 60 2014 384 391
54. C.D. Byrne Ectopic fat, insulin resistance and non-alcoholic fatty liver disease Proc Nutr Soc 72 2013 412 419
55. K. Kantartzis, J. Machann, F. Schick, A. Fritsche, H.U. Haring, and N. Stefan The impact of liver fat vs. visceral fat in determining categories of prediabetes Diabetologia 53 2010 882 889
56. Z. Gao, J. Zhang, I. Kheterpal, N. Kennedy, R.J. Davis, and J. Ye Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity J Biol Chem 24 2011 22227 22234
57. V.T. Samuel, Z.X. Liu, X. Qu, B.D. Elder, S. Bilz, D. Befroy, and et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease J Biol Chem 30 2004 32345 32353
58. C.D. Byrne Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management Diabet Med 29 2012 1098 1107
59. W.Z. Mehal The Gordian Knot of dysbiosis, obesity and NAFLD Nat Rev Gastroenterol Hepatol 10 2013 637 644
60. F.R. Jornayvaz, and G.I. Shulman Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance Cell Metab 15 2012 574 584
61. V.T. Samuel, and G.I. Shulman Mechanisms for insulin resistance: common threads and missing links Cell 148 2012 852 871
62. K. Yamaguchi, L. Yang, S. McCall, J. Huang, X.X. Yu, S.K. Pandey, and et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis Hepatology 45 2007 1366 1374
63. S. Schenk, M. Saberi, and J.M. Olefsky Insulin sensitivity: modulation by nutrients and inflammation J Clin Invest 118 2008 2992 3002
64. A. Leroux, G. Ferrere, V. Godie, F. Cailleux, M.L. Renoud, F. Gaudin, and et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis J Hepatol 57 2012 141 149
65. R.J. Perry, V.T. Samuel, K.F. Petersen, and G.I. Shulman The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes Nature 510 2014 84 91
66. M.J. Watt, A.C. Barnett, C.R. Bruce, S. Schenk, J.F. Horowitz, and A.J. Hoy Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesised ceramide Diabetologia 55 2012 2741 2746
67. G. Yang, L. Badeanlou, J. Bielawski, A.J. Roberts, Y.A. Hannun, and F. Samad Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome Am J Physiol Endocrinol Metab 297 2009 E211 E224
68. R.N. Kolesnick, and M. Kronke Regulation of ceramide production and apoptosis Annu Rev Physiol 60 1998 643 665
69. C. Lipina, and H. Hundal Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance Diabetologia 1 2011 1596 1607
70. J.L. Cantley, T. Yoshimura, J.P. Camporez, D. Zhang, F.R. Jornayvaz, N. Kumashiro, and et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance Proc Natl Acad Sci U S A 110 2013 1869 1874
71. G.S. Hotamisligil Endoplasmic reticulum stress and the inflammatory basis of metabolic disease Cell 140 2010 900 917
72. H. Tilg, and A.R. Moschen Insulin resistance, inflammation, and non-alcoholic fatty liver disease Trends Endocrinol Metab 19 2008 371 379
73. G. Targher, and C.D. Byrne Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications J Clin Endocrinol Metab 98 2013 483 495
74. J.H. Ix, and K. Sharma Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK J Am Soc Nephrol 21 2010 406 412
75. G. Targher, C.P. Day, and E. Bonora Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease N Engl J Med 363 2010 1341 1350
76. L.S. Bhatia, N.P. Curzen, P.C. Calder, and C.D. Byrne Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33 2012 1190 1200
77. E.T. Oni, A.S. Agatston, M.J. Blaha, J. Fialkow, R. Cury, A. Sposito, and et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 230 2013 258 267
78. S.H. Moon, T.S. Noh, Y.S. Cho, S.P. Hong, S.H. Hyun, J.Y. Choi, and et al. Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography Angiology 2014 [Epub ahead of print]
79. S. Ballestri, A. Lonardo, S. Bonapace, C.D. Byrne, P. Loria, and G. Targher Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease World J Gastroenterol 20 2014 1724 1745
80. M. Stepanova, and Z.M. Younossi Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population Clin Gastroenterol Hepatol 10 2012 646 650
81. G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, and et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diabetes Care 30 2007 1212 1218
82. V.W. Wong, G.L. Wong, G.W. Yip, A.O. Lo, J. Limquiaco, W.C. Chu, and et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease Gut 60 2011 1721 1727
83. S.A. Mirbagheri, A. Rashidi, S. Abdi, D. Saedi, and M. Abouzari Liver: an alarm for the heart? Liver Int 27 2007 891 894
84. U. Arslan, S. Turkoglu, S. Balcioglu, Y. Tavil, T. Karakan, and A. Cengel Association between nonalcoholic fatty liver disease and coronary artery disease Coron Artery Dis 18 2007 433 436
85. Y.J. Zhou, Y.Y. Li, Y.Q. Nie, C.M. Huang, and C.Y. Cao Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study J Dig Dis 13 2012 153 160
86. S. Treeprasertsuk, S. Leverage, L.A. Adams, K.D. Lindor, S.J. St, and P. Angulo The Framingham risk score and heart disease in nonalcoholic fatty liver disease Liver Int 32 2012 945 950
87. G. Targher, L. Bertolini, S. Rodella, R. Tessari, L. Zenari, G. Lippi, and et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients Diabetes Care 30 2007 2119 2121
88. C. Soderberg, P. Stal, J. Askling, H. Glaumann, G. Lindberg, J. Marmur, and et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up Hepatology 51 2010 595 602
89. N. Rafiq, C. Bai, Y. Fang, M. Srishord, A. McCullough, T. Gramlich, and et al. Long-term follow-up of patients with nonalcoholic fatty liver Clin Gastroenterol Hepatol 7 2009 234 238
90. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Boparai, Y.C. Liu, and A.J. McCullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419
91. M. Lazo, R. Hernaez, S. Bonekamp, I.R. Kamel, F.L. Brancati, E. Guallar, and et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study BMJ 343 2011 d6891
92. D. Kim, W.R. Kim, H.J. Kim, and T.M. Therneau Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States Hepatology 57 2013 1357 1365
93. P. Jepsen, H. Vilstrup, L. Mellemkjaer, A.M. Thulstrup, J.H. Olsen, J.A. Baron, and et al. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study Hepatogastroenterology 50 2003 2101 2104
94. R. Haring, H. Wallaschofski, M. Nauck, M. Dorr, S.E. Baumeister, and H. Volzke Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels Hepatology 50 2009 1403 1411
95. M. Hamaguchi, T. Kojima, N. Takeda, C. Nagata, J. Takeda, H. Sarui, and et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease World J Gastroenterol 13 2007 1579 1584
96. M.A. Dunn, J. Behari, S.S. Rogal, M.R. O'Connell, A. Furlan, A. Aghayev, and et al. Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes Liver Int 33 2013 1575 1582
97. S. Dam-Larsen, M. Franzmann, I.B. Andersen, P. Christoffersen, L.B. Jensen, T.I. Sorensen, and et al. Long term prognosis of fatty liver: risk of chronic liver disease and death Gut 53 2004 750 755
98. L.A. Adams, J.F. Lymp, S.J. St, S.O. Sanderson, K.D. Lindor, A. Feldstein, and et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 2005 113 121
99. G. Perseghin, G. Lattuada, C.F. De, A. Esposito, E. Belloni, G. Ntali, and et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver Hepatology 47 2008 51 58
100. R. Lautamaki, R. Borra, P. Iozzo, M. Komu, T. Lehtimaki, M. Salmi, and et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes Am J Physiol Endocrinol Metab 291 2006 E282 E290
101. L.J. Rijzewijk, J.T. Jonker, R.W. van der Meer, M. Lubberink, H.W. de Jong, J.A. Romijn, and et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes J Am Coll Cardiol 56 2010 225 233
102. L.J. Rijzewijk, R.W. van der Meer, J.W. Smit, M. Diamant, J.J. Bax, S. Hammer, and et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus J Am Coll Cardiol 52 2008 1793 1799
103. K. Hallsworth, K.G. Hollingsworth, C. Thoma, D. Jakovljevic, G.A. Macgowan, Q.M. Anstee, and et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease J Hepatol 58 2013 757 762
104. S. Bonapace, G. Perseghin, G. Molon, G. Canali, L. Bertolini, G. Zoppini, and et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes Diabetes Care 35 2012 389 395
105. N.H. Kim, J. Park, S.H. Kim, Y.H. Kim, D.H. Kim, G.Y. Cho, and et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population Heart 100 2014 938 943
106. H. Alp, S. Karaarslan, E.B. Selver, M.E. Atabek, H. Altin, and T. Baysal Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents Can J Cardiol 29 2013 1118 1125
107. G.K. Singh, B.E. Vitola, M.R. Holland, T. Sekarski, B.W. Patterson, F. Magkos, and et al. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease J Pediatr 162 2013 1160 1168 1168
108. A. Sert, E. Aypar, O. Pirgon, H. Yilmaz, D. Odabas, and I. Tolu Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease Am J Cardiol 112 2013 436 443
109. D. Fintini, M. Chinali, G. Cafiero, C. Esposito, U. Giordano, A. Turchetta, and et al. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD Nutr Metab Cardiovasc Dis 24 2014 72 74
110. L. Pacifico, M.M. Di, M.A. De, M. Bezzi, J.F. Osborn, C. Catalano, and et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease Hepatology 59 2014 461 470
111. R. Dhingra, P. Gona, T.J. Wang, C.S. Fox, R.B. D'Agostino Sr., and R.S. Vasan Serum gamma-glutamyl transferase and risk of heart failure in the community Arterioscler Thromb Vasc Biol 30 2010 1855 1860
112. S.G. Wannamethee, P.H. Whincup, A.G. Shaper, L. Lennon, and N. Sattar Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men Arterioscler Thromb Vasc Biol 32 2012 830 835
113. M.F. Sinner, N. Wang, C.S. Fox, J.D. Fontes, M. Rienstra, J.W. Magnani, and et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation Am J Cardiol 111 2013 219 224
114. A. Alonso, J.R. Misialek, M.A. Amiin, R.C. Hoogeveen, L.Y. Chen, S.K. Agarwal, and et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort Heart 100 2014 1151 1156
115. G. Targher, A. Mantovani, I. Pichiri, R. Rigolon, M. Dauriz, G. Zoppini, and et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes Clin Sci (Lond) 125 2013 301 309
116. G. Targher, F. Valbusa, S. Bonapace, L. Bertolini, L. Zenari, S. Rodella, and et al. Non-alcoholic Fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes PLoS One 8 2013 e57183
117. G. Targher, F. Valbusa, S. Bonapace, L. Bertolini, L. Zenari, I. Pichiri, and et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes Nutr Metab Cardiovasc Dis 24 2014 663 669
118. A. Algra, J.G. Tijssen, J.R. Roelandt, J. Pool, and J. Lubsen QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest Circulation 83 1991 1888 1894
119. J. Robbins, J.C. Nelson, P.M. Rautaharju, and J.S. Gottdiener The association between the length of the QT interval and mortality in the Cardiovascular Health Study Am J Med 115 2003 689 694
120. J.L. Newton, J. Pairman, K. Wilton, D.E. Jones, and C. Day Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease Clin Auton Res 19 2009 319 326
121. C.M. Otto, and B. Prendergast Aortic-valve stenosis-from patients at risk to severe valve obstruction N Engl J Med 371 2014 744 756
122. A. Rossi, G. Targher, G. Zoppini, M. Cicoira, S. Bonapace, C. Negri, and et al. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes Diabetes Care 35 2012 1781 1786
123. M.R. Markus, S.E. Baumeister, J. Stritzke, M. Dorr, H. Wallaschofski, H. Volzke, and et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP) Arterioscler Thromb Vasc Biol 33 2013 1690 1695
124. S. Bonapace, F. Valbusa, L. Bertolini, I. Pichiri, A. Mantovani, A. Rossi, and et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus PLoS One 9 2014 e88371
125. G. Targher, M. Chonchol, G. Zoppini, C. Abaterusso, and E. Bonora Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 54 2011 1020 1029
126. G. Targher, M.B. Chonchol, and C.D. Byrne CKD and nonalcoholic fatty liver disease Am J Kidney Dis 64 2014 638 652
127. G. Targher, L. Bertolini, S. Rodella, G. Zoppini, G. Lippi, C. Day, and et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients Diabetologia 51 2008 444 450
128. G. Targher, L. Bertolini, M. Chonchol, S. Rodella, G. Zoppini, G. Lippi, and et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients Diabetologia 53 2010 1341 1348
129. S.T. Hwang, Y.K. Cho, J.W. Yun, J.H. Park, H.J. Kim, D.I. Park, and et al. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes Intern Med J 40 2010 437 442
130. G. Targher, I. Pichiri, G. Zoppini, M. Trombetta, and E. Bonora Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver Diabet Med 29 2012 220 226
131. G. Li, W. Shi, H. Hug, Y. Chen, L. Liu, and D. Yin Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population Biochem Med (Zagreb) 22 2012 92 99
132. A.L. Ahn, J.K. Choi, M.N. Kim, S.A. Kim, E.J. Oh, H.J. Kweon, and et al. Non-alcoholic fatty liver disease and chronic kidney disease in Koreans aged 50 years or older Korean J Fam Med 34 2013 199 205
133. G. Targher, L. Bertolini, S. Rodella, G. Lippi, G. Zoppini, and M. Chonchol Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis Clin J Am Soc Nephrol 5 2010 2166 2171
134. Y. Yilmaz, Y.O. Alahdab, O. Yonal, R. Kurt, A.E. Kedrah, C.A. Celikel, and et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis Metabolism 59 2010 1327 1330
135. K. Yasui, Y. Sumida, Y. Mori, H. Mitsuyoshi, M. Minami, Y. Itoh, and et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease Metabolism 60 2011 735 739
136. M.V. Machado, S. Goncalves, F. Carepa, J. Coutinho, A. Costa, and H. Cortez-Pinto Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease Liver Int 32 2012 241 248
137. G. Targher, M. Chonchol, L. Bertolini, S. Rodella, L. Zenari, G. Lippi, and et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease J Am Soc Nephrol 19 2008 1564 1570
138. Y. Chang, S. Ryu, E. Sung, H.Y. Woo, E. Oh, K. Cha, and et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men Metabolism 57 2008 569 576
139. Y. Arase, F. Suzuki, M. Kobayashi, Y. Suzuki, Y. Kawamura, N. Matsumoto, and et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease Intern Med 50 2011 1081 1087
140. G. Targher, A. Mantovani, I. Pichiri, L. Mingolla, V. Cavalieri, W. Mantovani, and et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes Diabetes Care 37 2014 1729 1736
141. L.A. Stevens, J. Coresh, T. Greene, and A.S. Levey Assessing kidney function-measured and estimated glomerular filtration rate N Engl J Med 354 2006 2473 2483
142. E. Bonora, and G. Targher Increased risk of cardiovascular disease and chronic kidney disease in NAFLD Nat Rev Gastroenterol Hepatol 9 2012 372 381
143. S.E. Shoelson, L. Herrero, and A. Naaz Obesity, inflammation, and insulin resistance Gastroenterology 132 2007 2169 2180
144. N. Stefan, and H.U. Haring The role of hepatokines in metabolism Nat Rev Endocrinol 9 2013 144 152
145. C.D. Byrne, and G. Targher Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease Arterioscler Thromb Vasc Biol 34 2014 1155 1161
146. G. Targher, and C.D. Byrne Diagnosis and management of nonalcoholic Fatty liver disease and its hemostatic/thrombotic and vascular complications Semin Thromb Hemost 39 2013 214 228
147. A. Lonardo, S. Ballestri, G. Targher, and P. Loria Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease Expert Rev Gastroenterol Hepatol 20 2014 1 22